TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21962070
Drug: Intravenous iron(III)‐hydroxide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous iron(III)‐hydroxide sucrose (200 mg)
Study: 9176645
Drug: Inhaled budesonide
Normalized name: budesonide Inhalation Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled budesonide 0.8 mg b.i.d.
Study: 8222166
Drug: omega-3 fatty
Normalized name: Omega-3 fatty acid
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: omega-3 fatty acids (3 g/d)
Study: 23575211
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D3 20,000 IU twice per week
Study: 16036503
Drug: Pantoprazole (PAN)
DrugBank: Pantoprazole (DB00213)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pantoprazole (PAN) 8 mg/h + 80 mg bolus
Study: 12585170
Drug: Zhongfeng No.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zhongfeng No. II Oral Liquid (ZF II) plus western medicine
Study: 12585170
Drug: Zhongfeng No.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zhongfeng No. II Oral Liquid (ZF II) in animal model
Study: 9312759
Drug: Oral glucose
Normalized name: glucose Oral Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral glucose tolerance test (75 g) and i.v. glucagon test (1 mg)
Study: 3827456
Drug: Deflazacort (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deflazacort (30 mg/d for four weeks)
Study: 3827456
Drug: Prednisone (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone (25 mg/d for four weeks)
Study: 30477836
Drug: Painting and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Painting and handcrafting group art therapy (creative art therapy) for one month
Study: 22456105
Drug: Group B:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group B: Sexual intercourse twice a week for 3 months
Study: 20107105
Drug: ROSI 4
Normalized name: EMROSI 40mg Extended-Release Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: ROSI 4 mg b.i.d.
Study: 20107105
Drug: EXE 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: EXE 10 microg b.i.d. + ROSI 4 mg b.i.d.
Study: 15800988
Drug: Device that
Approvals — FDA: no, EMA: no, PMDA: no
Description: Device that applies kneading-like motion on the abdomen, used once daily for 20 min for 12 weeks
Study: 12777952
Drug: Hormone Replacement
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormone Replacement Therapy (HRT) - 0.625 mg of conjugated equine estrogen combined with 2.5 mg of medroxyprogesterone acetate, administered once a day orally for 12 months
Study: 10392351
Drug: Chemotherapy (CT)
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (CT) during induction
Study: 10392351
Drug: Chemotherapy (CT)
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (CT) at the end of CNS-directed therapy
Study: 10392351
Drug: Neutrophil count
Normalized name: brain-derived neurotrophic factor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neutrophil count above 1 x 10(9)/l during continuation chemotherapy
Study: 10392351
Drug: Neutrophil count
Normalized name: brain-derived neurotrophic factor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neutrophil count less than 1 x 10(9)/l during continuation chemotherapy
Study: 8540453
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil group (4 g/day of fish oil concentrate)
Study: 19564670
Drug: Intermittent negative
Normalized name: GLYCERIN NEGATIVE CONTROL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent negative pressure wound therapy (NPWT) at lower pressures (‐75 mm Hg or ‐100 mm Hg)
Study: 19564670
Drug: Continuous negative
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous negative pressure wound therapy (NPWT) at higher pressure (‐125 mm Hg)
Study: 17520151
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of keratin peptide treatment
Study: 17520151
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of keratin-active formulation
Study: 14732296
Drug: Ascorbic acid
Normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ascorbic acid (final concentration 0.1, 1.0, and 10 mmol/L)
Study: 11683967
Drug: Intravesical BCG
Normalized name: BCG, live, Tice strain
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravesical BCG therapy (21 patients)
Study: 11683967
Drug: Mitomycin C
Normalized name: Mitomycin C
DrugBank: Mitomycin (DB00305)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mitomycin C plus doxorubicin therapy (21 patients)
Study: 11683967
Drug: Subsequent instillation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subsequent instillation of the other intravesical therapy for non-responders
Study: 11683967
Drug: Both therapies
Normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both therapies (BCG and mitomycin C plus doxorubicin)
Study: 9843104
Drug: Thalidomide 400
Normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Thalidomide 400 mg daily for 5 days
Study: 7857507
Drug: Hypericum extract
Normalized name: Hypericum extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypericum extract LI 160 (300 mg three times daily)
Study: 356720
Drug: Calcium carbonate
Normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium carbonate (CaCO3, 2 g/day)
Study: 356720
Drug: Calcium p-chlorphenoxyisobutyrate
Normalized name: docusate calcium / phenolphthalein Oral Capsule [Docucal-P]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium p-chlorphenoxyisobutyrate (Ca-CPIB, 2 g/day)
Study: 356720
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of CaCO3 and Ca-CPIB
Study: 356720
Drug: Calcium p-chlorphenoxyisobutyrate
Normalized name: docusate calcium / phenolphthalein Oral Capsule [Docucal-P]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium p-chlorphenoxyisobutyrate (Ca-CPIB, either singly or in combination)
Study: 12779198
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg intravenous metoclopramide 8-hourly for 48 hours
Study: 12779198
Drug: 5% saline
Normalized name: Breathe Free 0.65% Saline Nasal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% saline (control) 8-hourly for 48 hours
Study: 9338902
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg intravenous metoclopramide
Study: 10882145
Drug: Fluoxetine (FL)
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluoxetine (FL) 40 mg single dose
Study: 10882145
Drug: Fluoxetine (FL)
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluoxetine (FL) 60 mg per day for 12 weeks
Study: 10882145
Drug: Fluoxetine (FL)
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluoxetine (FL) and Placebo (PL)
Study: 3517250
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with LAK cells and IL-2
Study: 23929659
Drug: Darexaban 60
Normalized name: Darexaban
DrugBank: Darexaban (DB12289)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Darexaban 60 mg
Study: 27128609
Drug: Darexaban 60
Normalized name: Darexaban
DrugBank: Darexaban (DB12289)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Darexaban 60 mg with ketoconazole 400 mg once daily on Days 1-9
Study: 19597409
Drug: Ketoprofen 10%
Normalized name: KETOPROFEN 10% CREAM,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoprofen 10% spray gel (360 mg/die)
Study: 19597409
Drug: Oral ketoprofen
Normalized name: Ketoprofen
DrugBank: Ketoprofen (DB01009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral ketoprofen (25 mg t.i.d.)
Study: 19597409
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no pharmacological treatment)
Study: 19597409
Drug: Ketoprofen 10%
Normalized name: KETOPROFEN 10% CREAM,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoprofen 10% spray gel
Study: 14601367
Drug: Epoetin alpha
Normalized name: Epoetin
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epoetin alpha as an adjuvant treatment to preoperative autologous blood donation (PAD) program (40,000 IU weekly for 21, 14, and 7 days before surgery)
Study: 14601367
Drug: Epoetin alpha
Normalized name: Epoetin
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epoetin alpha alone (2 doses weekly for the same period)
Study: 1332737
Drug: Metoclopramide 2
Normalized name: metoclopramide 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide 2 mg/kg every 2 h for five doses plus dexamethasone 10 mg and diphenhydramine
Study: 4065703
Drug: Continuous intravenous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous intravenous morphine infusion
Study: 1773325
Drug: Intermittent intramuscular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent intramuscular morphine
Study: 23749153
Drug: Half-molar sodium
Normalized name: Polar Freeze
Approvals — FDA: no, EMA: no, PMDA: no
Description: Half-molar sodium lactate (SL) infusion at 0.5 ml/kg/h for 48 hours
Study: 23749153
Drug: Isotonic saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isotonic saline solution (control group)
Study: 23749153
Drug: Half-molar sodium
Normalized name: Polar Freeze
Approvals — FDA: no, EMA: no, PMDA: no
Description: Half-molar sodium lactate (SL) infusion
Study: 11445478
Drug: Flaxseed-supplemented, fat-restricted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flaxseed-supplemented, fat-restricted diet (30 g/day flaxseed, 20% of kilocalories or less from fat)
Study: 8062886
Drug: Interleukin-3 (IL-3)
Normalized name: interleukin-3
DrugBank: Muplestim (DB12431)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interleukin-3 (IL-3) at doses of 0.5, 1.25, 2.5, 5.0, or 10 micrograms/kg/d by subcutaneous injection for 21-day cycles
Study: 8062886
Drug: Interleukin-3 (IL-3)
Normalized name: interleukin-3
DrugBank: Muplestim (DB12431)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interleukin-3 (IL-3) at doses of 5.0 micrograms/kg/d or higher
Study: 3064773
Drug: Breast-preserving therapy
Normalized name: chicken breast preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Breast-preserving therapy
Study: 3064773
Drug: Non-randomized group
Normalized name: jojoba oil, randomized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-randomized group (breast-preserving therapy)
Study: 29146650
Drug: Iron syrup
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron syrup (12.5 mg elemental iron)
Study: 29146650
Drug: Multiple micronutrient
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple micronutrient powders (MMPs including 12.5 mg elemental iron)
Study: 26686508
Drug: DTP-HB-Hib vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTP-HB-Hib vaccine (3 doses with 4-week intervals)
Study: 15080855
Drug: SR 48692
Normalized name: SR 121463
DrugBank: SR 121463 (DB05455)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SR 48692 (90 mg)
Study: 15080855
Drug: SR 48692
Normalized name: SR 121463
DrugBank: SR 121463 (DB05455)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SR 48692 (300 mg)
Study: 15080855
Drug: SR 48692
Normalized name: SR 121463
DrugBank: SR 121463 (DB05455)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SR 48692 (90 mg) and (300 mg)
Study: 9313662
Drug: 130 mg
Normalized name: pectin 130 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 130 mg free beta-sitosterol daily
Study: 2444962
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of lysine
Study: 27055427
Drug: Aerosolized N-acetylcysteine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aerosolized N-acetylcysteine (NAC), administered starting within 12 hours of mechanical ventilation, once every 8 hours until stopping mechanical ventilation.
Study: 24361248
Drug: Amrubicin (40-45
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amrubicin (40-45 mg/m² for ages 70-74; 40 mg/m² for ages ≥ 75) intravenously on days 1-3 every 3 weeks for 4-6 cycles
Study: 24361248
Drug: Carboplatin (AUC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carboplatin (AUC 5 on day 1) and Etoposide (80 mg/m² on days 1-3) every 3 weeks for 4-6 cycles
Study: 3756312
Drug: Bestatin treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bestatin treatment (daily oral administration)
Study: 28938325
Drug: Dexpanthenol-vitamin A
Normalized name: Dexpanthenol
DrugBank: Dexpanthenol (DB09357)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dexpanthenol-vitamin A (Nazalnem) ointment applied to silastic splints
Study: 27198947
Drug: GEn 600
Normalized name: collagen 6000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: GEn 600 mg
Study: 27198947
Drug: GEn 1200
Normalized name: Vibrio cholerae CVD 103-HGR strain live antigen 12000000 UNT/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: GEn 1200 mg
Study: 25874578
Drug: GEn 600
Normalized name: collagen 6000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: GEn 600 mg and 1200 mg
Study: 19772448
Drug: Standard Options
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard Options + AIR insulin
Study: 17425817
Drug: Ondansetron 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron 0.2 mg mL-1 with PCA morphine
Study: 7492487
Drug: Cyclosporine G
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporine G
Study: 3732088
Drug: Potassium-conserving diuretic
Normalized name: Potassium
DrugBank: Potassium (DB14500)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Potassium-conserving diuretic (amiloride)
Study: 3732088
Drug: Potassium-losing diuretic
Normalized name: Potassium
DrugBank: Potassium (DB14500)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Potassium-losing diuretic (chlorthalidone)
Study: 31058784
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy control
Study: 16674762
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg diclofenac potassium sachets
Study: 16674762
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg diclofenac potassium tablets
Study: 16674762
Drug: Both sachets
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both sachets and tablets
Study: 8791970
Drug: Cisapride, 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisapride, 20 mg t.d.s.
Study: 10155556
Drug: Short-term steroid
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short-term steroid therapy and PE with anti-viral therapy
Study: 10155556
Drug: Anti-viral agents
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-viral agents and PE
Study: 3898417
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg ranitidine at night
Study: 6099915
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg cimetidine at night
Study: 25499341
Drug: Intravenous fasudil
Normalized name: fasudil
DrugBank: Fasudil (DB08162)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Intravenous fasudil (30 mg over 30 min)
Study: 25499341
Drug: Inhaled iloprost
Normalized name: iloprost Inhalation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled iloprost (5 μg)
Study: 22521630
Drug: Intramuscular botulinum
Normalized name: Clostridium botulinum
DrugBank: Clostridium botulinum (DB14223)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular botulinum toxin A
Study: 8682116
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (atenolol + nifedipine)
Study: 1899852
Drug: Alpha-interferon (7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alpha-interferon (7.5 MU/m2 three times weekly for 3 months, then 5 MU/m2 for 3 months, and 2.5 MU/m2 for 6 months)
Study: 30252057
Drug: 11β‐MNTDC (100,
Approvals — FDA: no, EMA: no, PMDA: no
Description: 11β‐MNTDC (100, 200, 400, and 800 mg)
Study: 30252057
Drug: 11β‐MNTDC (200,
Approvals — FDA: no, EMA: no, PMDA: no
Description: 11β‐MNTDC (200, 400, and 800 mg)
Study: 29176264
Drug: Chondroitin sulfate
Normalized name: Chondroitin Sulfate
DrugBank: Chondroitin sulfate (DB09301)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chondroitin sulfate 1560 mg/d
Study: 29176264
Drug: Chondroitin sulfate
Normalized name: Chondroitin Sulfate
DrugBank: Chondroitin sulfate (DB09301)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chondroitin sulfate 260 mg/d (low-dose group, control group)
Study: 15094439
Drug: Radio-guided tumour
Normalized name: human breast tumor cell
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radio-guided tumour excision after intratumoral injection of 99mTc-nanocolloid
Study: 9052605
Drug: Endovaginal ultrasound
Normalized name: ULTRASOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endovaginal ultrasound (weekly vaginal probe ultrasound scans)
Study: 8367670
Drug: IVER 400
Normalized name: Iver-On
Approvals — FDA: no, EMA: no, PMDA: no
Description: IVER 400 plus DEC 1 mg.kg‐1 (12 patients)
Study: 8367670
Drug: IVER 400
Normalized name: Iver-On
Approvals — FDA: no, EMA: no, PMDA: no
Description: IVER 400 plus DEC 3 mg.kg‐1 (17 patients)
Study: 8367670
Drug: IVER 400
Normalized name: Iver-On
Approvals — FDA: no, EMA: no, PMDA: no
Description: IVER 400 plus DEC 6 mg.kg‐1 (10 patients)
Study: 8367670
Drug: DEC 6
Normalized name: Zodryl DEC 60 Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: DEC 6 mg.kg‐1 alone (5 patients)
Study: 2738261
Drug: Sequential pulse
Normalized name: dulse extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential pulse defibrillation
Study: 26988949
Drug: Aspirin plus
Normalized name: Aspirin Plus Antacid Extra Strength
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin plus prasugrel
Study: 27845859
Drug: 25-hydroxyvitamin D
Normalized name: 25-hydroxyvitamin D
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25-hydroxyvitamin D (25-OHD) levels in women with MetS (35.26 ± 1.61 nmol/l)
Study: 16790650
Drug: Levobupivacaine 0.125%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levobupivacaine 0.125% and sufentanil 0.75 microg/mL with epinephrine 1:800,000
Study: 16790650
Drug: Levobupivacaine 0.125%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levobupivacaine 0.125% and sufentanil 0.75 microg/mL without epinephrine
Study: 11103159
Drug: Cephalosporin antibiotic
Normalized name: Cephalosporium roseum
DrugBank: Cephalosporium roseum (DB10932)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cephalosporin antibiotic
Study: 9396959
Drug: Sertraline or
Normalized name: sertraline Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline or paroxetine (SSRIs) for 6 weeks
Study: 19747930
Drug: Intranasal administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal administration of oxytocin
Study: 20451523
Drug: Lesogaberan (65
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lesogaberan (65 mg)
Study: 18564348
Drug: 500 mcg
Normalized name: Nplate 500 MCG Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mcg alprostadil cream
Study: 18564348
Drug: 700 mcg
Normalized name: L-Methylfolate Glucosamine 1700 MCG Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 700 mcg alprostadil cream
Study: 18564348
Drug: 900 mcg
Normalized name: Belbuca 900 MCG Buccal Film
Approvals — FDA: no, EMA: no, PMDA: no
Description: 900 mcg alprostadil cream
Study: 16167910
Drug: Diclofenac hydroxyethyl
Normalized name: diclofenac hydroxyethylpyrrolidine 1.292 % Topical Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac hydroxyethyl pyrrolidine (100 mg)
Study: 12859696
Drug: losartan (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: losartan (50 mg o.d.)
Study: 11130221
Drug: Prokinetic agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prokinetic agents (cisapride, erythromycin, metoclopramide)
Study: 8157039
Drug: Atenolol 100
Normalized name: atenolol 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol 100 mg (AT)
Study: 8157039
Drug: Bendrofluazide 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bendrofluazide 5 mg (BFZ)
Study: 8157039
Drug: Combined Atenolol
Normalized name: Atenolol
DrugBank: Atenolol (DB00335)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Combined Atenolol 100 mg and Bendrofluazide 5 mg (AT/BFZ)
Study: 8157039
Drug: Diazepam 5
Normalized name: diazepam 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam 5 mg (Dz)
Study: 3538476
Drug: Inhaled piriprost
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled piriprost 1 mg
Study: 26179891
Drug: Dietary counseling
Normalized name: sodium phosphate, monobasic
DrugBank: Sodium phosphate, monobasic (DB09449)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dietary counseling and n-3 PUFA supplementation (2.4 g/d) for 36 months
Study: 23726602
Drug: Mizoribine (MZR)
Normalized name: Mizoribine
DrugBank: Mizoribine (DB12617)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mizoribine (MZR) after dose change
Study: 23726602
Drug: Mycophenolate mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mycophenolate mofetil (MMF) after dose change
Study: 18582179
Drug: d-MPH-ER 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: d-MPH-ER 20 mg/day
Study: 18582179
Drug: d-MPH-ER 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: d-MPH-ER 30 mg/day
Study: 18582179
Drug: d,l-MPH-ER 36
Approvals — FDA: no, EMA: no, PMDA: no
Description: d,l-MPH-ER 36 mg/day
Study: 16861611
Drug: GHRP-2 low
Normalized name: Dianeal Low Calcium 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: GHRP-2 low dose (0.1 microg/kg per hour)
Study: 16861611
Drug: GHRP-2 high
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: GHRP-2 high dose (1 mug/kg per hour)
Study: 14561022
Drug: Acid suppressive
Normalized name: Buckley's Cough Suppressant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acid suppressive therapy (AST)
Study: 14561022
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (surgical and general internal medicine ward)